WO2024110905 - ANTI-CEA ANTIBODY DRUG CONJUGATES AND METHODS OF USE
National phase entry:
Publication Number
WO/2024/110905
Publication Date
30.05.2024
International Application No.
PCT/IB2023/061813
International Filing Date
22.11.2023
Title **
[English]
ANTI-CEA ANTIBODY DRUG CONJUGATES AND METHODS OF USE
[French]
CONJUGUÉS ANTICORPS ANTI-CEA-MÉDICAMENT ET PROCÉDÉS D'UTILISATION
Applicants **
BEIGENE GUANGZHOU BIOLOGICS MANUFACTURING CO., LTD.
BEIGENE SWITZERLAND GMBH
Inventors
TSAI, Charng-Sheng
TSAI, Mei-Hsuan
QU, Liang
WEI, Xiaodong
WANG, Zewei
LUO, Wei
HE, Maomao
LI, Zhuo
Priority Data
PCT/CN2022/134067
24.11.2022
CN
PCT/CN2023/107003
12.07.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4355 | |
| EPO | Filing, Examination, Granting | 25206 | |
| Japan | Filing, Examination, Granting | 2772 | |
| South Korea | Filing, Examination, Granting | 3362 | |
| USA | Filing, Examination, Granting | 11940 |
Total:
47,635
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides antibody drug conjugates comprising antibodies and antigen-binding fragments thereof that bind to human CEA and a linker-payload, a pharmaceutical composition comprising the anti-CEA antibody drug conjugate, and use of the anti-CEA antibody drug conjugate for treating a CEA-related diseases or disorders.[French]
La présente invention concerne des conjugués anticorps-médicament comprenant des anticorps et des fragments de liaison à l'antigène de ceux-ci qui se lient au CEA humain et une charge utile de lieur, une composition pharmaceutique comprenant le conjugué anticorps anti-CEA-médicament, et l'utilisation du conjugué anticorps anti-CEA-médicament pour traiter des maladies ou des troubles liés au CEA.